Arshad M. Khanani, MD, reflects on updates he has integrated into his practice following insights from the AAO 2024 annual meeting's retina subspecialty day. Dr Khanani highlights recent research on neovascular AMD, emphasizing Dr Barbara Blodi’s findings on macular atrophy and extending treatment intervals for stable patients.
Dr Khanani also discusses advancements in identifying fibrosis biomarkers, particularly via OCT imaging, and combination therapies for polypoidal choroidal vasculopathy (PCV). Dr Khanani concludes with his own groundbreaking AAO presentation on ABBV-RGX-314 gene therapy, which demonstrates substantial reduction in treatment needs and shows promise for bilateral dosing in patients with AMD.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: AAO 2024: New Horizons in the Treatment of Wet AMD - Medscape - Nov 12, 2024.
Comments